Production (Stage)
Tenax Therapeutics, Inc.
TENX
$6.07
$0.020.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 358.64% | 64.55% | 43.30% | 29.48% | -3.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 190.05% | 118.34% | 118.14% | 197.04% | 153.91% |
| Operating Income | -190.05% | -118.34% | -118.14% | -197.04% | -153.91% |
| Income Before Tax | -173.97% | -94.27% | -100.84% | -223.21% | -170.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -173.97% | -94.27% | -100.84% | -223.21% | -170.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.97% | -94.27% | -100.84% | -223.21% | -170.05% |
| EBIT | -190.05% | -118.34% | -118.14% | -197.04% | -153.91% |
| EBITDA | -- | -118.62% | -118.15% | -197.13% | -153.93% |
| EPS Basic | 90.87% | 98.35% | 97.17% | 54.37% | 74.25% |
| Normalized Basic EPS | 90.87% | 98.36% | 97.17% | 54.37% | 74.18% |
| EPS Diluted | 90.87% | 98.35% | 97.17% | 54.37% | 74.25% |
| Normalized Diluted EPS | 90.87% | 98.36% | 97.17% | 54.37% | 74.18% |
| Average Basic Shares Outstanding | 2,900.98% | 11,712.01% | 6,993.90% | 608.21% | 948.24% |
| Average Diluted Shares Outstanding | 2,900.98% | 11,712.01% | 6,993.90% | 608.21% | 948.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |